Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.
18F-fluorocholine PET/CT outcome
223radium
bone scintigraphy
prostate cancer
Journal
Future science OA
ISSN: 2056-5623
Titre abrégé: Future Sci OA
Pays: England
ID NLM: 101665030
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
21
04
2021
accepted:
07
05
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
epublish
Résumé
To assess the value of bone scintigraphy and Retrospective analysis of 48 patients that underwent After therapy, pain relief was observed in 27 patients. Patients without pain relief had more bone lesions at PET/CT than at bone scintigraphy (pretherapy imaging mismatch). In 39 patients who completed treatment protocol, post-therapy alkaline phosphatase and pretherapy imaging mismatch were independent predictors of poor overall survival. Patients with more lesions at
Identifiants
pubmed: 34295537
doi: 10.2144/fsoa-2021-0053
pmc: PMC8288237
doi:
Types de publication
Journal Article
Langues
eng
Pagination
FSO719Informations de copyright
© 2021 Alberto Cuocolo.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Références
Eur J Radiol. 2012 Aug;81(8):e893-6
pubmed: 22621862
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Clin Transl Oncol. 2019 Mar;21(3):289-297
pubmed: 30006674
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):84-91
pubmed: 26323576
Oncologist. 2009 Aug;14(8):816-27
pubmed: 19684076
Nucl Med Mol Imaging. 2015 Jun;49(2):160-4
pubmed: 26082811
PET Clin. 2018 Oct;13(4):491-503
pubmed: 30219184
Int Braz J Urol. 2020 Mar 15;46(4):599-611
pubmed: 32213206
Bone. 2006 Jul;39(1):35-41
pubmed: 16434248
Clin Nucl Med. 2013 May;38(5):305-14
pubmed: 23486334
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Tumori. 2019 Oct;105(5):367-377
pubmed: 31096849
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):84-96
pubmed: 28567494
Clin Genitourin Cancer. 2019 Feb;17(1):e187-e194
pubmed: 30448106
J Nucl Med. 2015 Aug;56(8):1177-84
pubmed: 26069307
Cancer. 1988 Jan 1;61(1):195-202
pubmed: 3334948
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712
Cancers (Basel). 2019 Dec 20;12(1):
pubmed: 31861942
Nat Rev Clin Oncol. 2011 Jan;8(1):12-23
pubmed: 20859283
J Nucl Med. 2015 Oct;56(10):1507-12
pubmed: 26135112
Clin J Pain. 1989 Jun;5(2):153-9
pubmed: 2520397
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1766-74
pubmed: 18465129
Biochem Biophys Res Commun. 2002 Aug 23;296(3):580-3
pubmed: 12176020
Eur J Cancer. 2014 Jun;50(9):1617-27
pubmed: 24703899
Int J Urol. 2017 Aug;24(8):566-572
pubmed: 28577511
Cancer. 2008 Feb 15;112(4):813-9
pubmed: 18098207
Lancet Oncol. 2014 Jun;15(7):738-46
pubmed: 24836273
Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):668-73
pubmed: 15765234
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1832-1844
pubmed: 28612079
Tumori. 2020 Oct;106(5):406-412
pubmed: 32116138
Onco Targets Ther. 2018 Dec 17;12:9-13
pubmed: 30588025
Endocr J. 1998 Feb;45(1):97-104
pubmed: 9625452
J Nucl Med. 2014 Feb;55(2):233-41
pubmed: 24408897
Clin Genitourin Cancer. 2013 Mar;11(1):20-6
pubmed: 23021204
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1873-1883
pubmed: 29766246